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Somatic Mutations in NEK9 Cause Nevus Comedonicus
Jonathan L. Levinsohn,1,2 Jeffrey L. Sugarman,3 Yale Center for Mendelian Genomics,
Jennifer M. McNiff,2,4 Richard J. Antaya,2,5 and Keith A. Choate1,2,4,*
Acne vulgaris (AV) affects most adolescents, and of those affected, moderate to severe disease occurs in 20%. Comedones, follicular plugs
consisting of desquamated keratinocytes and sebum, are central to its pathogenesis. Despite high heritability in first-degree relatives, AV
genetic determinants remain incompletely understood. We therefore employed whole-exome sequencing (WES) in nevus comedonicus
(NC), a rare disorder that features comedones and inflammatory acne cysts in localized, linear configurations. WES identified somatic
NEK9 mutations, each affecting highly conserved residues within its kinase or RCC1 domains, in affected tissue of three out of three
NC-affected subjects. All mutations are gain of function, resulting in increased phosphorylation at Thr210, a hallmark of NEK9 kinase
activation. We found that comedo formation in NC is marked by loss of follicular differentiation markers, expansion of keratin-15-pos-
itive cells from localization within the bulge to the entire sub-bulge follicle and cyst, and ectopic expression of keratin 10, a marker of
interfollicular differentiation not present in normal follicles. These findings suggest thatNEK9mutations in NC disrupt normal follicular
differentiation and identify NEK9 as a potential regulator of follicular homeostasis.Acne vulgaris (AV) is a common disorder affecting nearly
all adolescents, and it can range in severity from isolated
non-inflammatory open and closed comedones to raised
inflammatory lesions and pustules.1 The most severe cases
demonstrate nodulocystic inflammatory disease, and up
to 20% of affected individuals experience permanent
scarring.2
Microcomedones, which consist of plugs of desqua-
mated keratinocytes, are thought to be precursors to acne
lesions. These plugs trap sebum and keratin within folli-
cles, leading to the formation of dilated plugged follicles
known as comedones. The nutrient-rich environment
within the comedo can lead to overgrowth of P. acnes
and subsequent inflammation.3 Current treatment for AV
includes topical or systemic retinoids, antibiotics, and ben-
zoyl peroxide. These agents are thought to prevent comedo
formation and inflammation by promoting differentiation
of cells within the hair follicle unit, reducing sebum secre-
tion and sebocyte proliferation, and killing P. acnes.4
Genetic investigation of Mendelian acne phenotypes
has identified pathways implicated both in the generation
of comedones and in subsequent inflammatory responses.
Apert syndrome (MIM: 101200), a rare congenital disease
that presents with craniosynostosis, syndactyly, and severe
acne with comedones and inflammatory cysts, is caused
by heterozygous activating mutations in FGFR2 (MIM:
176943).5 Munro acne nevus is a localized form of Apert
syndrome that results from somatic FGFR2 mutation and
features linear groups of comedones and inflammatory
cysts.6 These disorders suggest that FGFR2 signaling might
be important both in comedogenesis and inflammation,
and mouse models have shown that FGFR2 is necessary
for skin and hair follicle homeostasis and regulation of
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matory acne found in axillary, inguinal, and perianal
regions, presents with comedones, inflammatory nodules,
and draining sinus tracts.9 A subset of individuals with
acne inversa have mutations in PSENEN (MIM: 607632),
PSEN1 (MIM: 104311), and NCSTN (MIM: 605254) which
act within the g-secretase pathway, implicating Notch
signaling defects in comedogenesis.10 Evidence in mouse
models suggests that, as in FGFR2 mutations, g-secretase
haploinsufficiency might promote comedo formation,
leading to subsequent inflammation.11
Genome-wide association studies (GWASs) in AV have
identified multiple loci associated with severe acne. A
GWAS involving Chinese Han individuals found two
loci, one near DDB2 (MIM: 600811) and the other within
SELL (MIM: 153240). These genes are thought to play
a role in anti-microbial activity of sebocytes (DDB2)
and mediation of cutaneous inflammation (SELL), respec-
tively.12 A GWAS involving European individuals found
three separate loci, containing the genes OVOL1 (MIM:
602313), FST (MIM: 136470), and TGFB2 (MIM: 190220),
all active in TGF-b signaling, which might modulate the
inflammatory response to comedonal lesions or play a
role in tissue remodeling.13,14
Nevus comedonicus (NC) is a severe, localized form
of acne estimated to be present in 1:45,000–1:100,000
births and appears in infancy as a linear shiny patch
with development of comedones early in life.15 Some
of these comedones can subsequently become inflamed
and form acne cysts, suggesting that NC lesions result
from a process that most directly leads to comedo devel-
opment with inflammation occurring as a secondary
consequence.1 The linear configuration of NC lesions
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Figure 1. Clinical and Histologic Features of Nevus Comedonicus
Three unrelated subjects presented with linear patches of comedones on distinct body sites. NC101, a 43-year-old woman, had a lesion
on the back that featured numerous dilated follicular ostia and comedones, with a scar inferiorly at the site of a prior inflammatory lesion
(A). NC102, a 10-year-old boy, had a lesion on the thigh that featured numerous comedones and atrophic scars at the sites of prior in-
flammatory lesions (B). NC103, a 19-year-old woman, had a hairless patch on the scalp. The patch subsequently never grew hair and
developed multiple comedones and inflammatory cysts (C). Intervening skin appeared grossly normal in all subjects. Histopathologic
examination of affected scalp excision tissue in subject NC103 revealed normal hair follicles (white arrows) adjacent to affected follicles
(black arrow), which show dilated follicular ostia, marked acanthosis and papllimatosis of the outer root sheath, and large cystic struc-
tures filled with keratin in the deep dermis (D). Examination of tissue excised from the back of subject NC101 shows an isolated follicle
with a dilated ostium, acanthosis and papillomatosis of the outer root sheath, and accumulated keratin in place of a hair shaft (E). In
both cases, interfollicular epidermis appears to be normal. Scale bars represent 1 mm.acquisition of a somatic mutation during embryonic
development.
In cutaneous mosaic disorders due to mutations within
keratinocyte precursors, including NC, skin lesions are
found in linear configurations known as lines of Blaschko,
which represent the dorsoventral migration of epithelial
progenitors.16 When multilineage somatic mosaicisim
occurs, more widespread involvement is seen, as in the
cutaneous-skeletal hypophosphatemic syndrome, which
features hypophosphatemic rickets, epidermal and mela-
nocytic nevi, and hamartomas in multiple organs as a
result of multilineage somatic activating RAS muta-
tions.17 Extracutaneous manifestations have also been
reported in individuals with NC, leading to the diagnosis
of nevus comedonicus syndrome, which can feature NC
lesions, ipsilateral cataracts, and neurological and skeletal
abnormalities.18
To determine the genetic cause of NC, we recruited a
cohort of three subjects with NC lesions, and consent
to a protocol approved by the Yale University human
investigation committee was obtained. All subjects had
a history of localized linear lesions featuring inter-
mixed non-inflammatory grouped comedones, scars,
and recurrent inflammatory cysts without other inter-
vening skin changes. Subjects provided a skin biopsy
from lesional tissue and a peripheral blood sample for
analysis.The AmericNC101, a 43-year-old woman, initially presented with a
6 cm 3 3 cm linear lesion consisting of grouped come-
dones on the back and a history of inflammatory cysts
within the lesion (Figure 1). NC102, a 10-year-old boy,
presented at birth with a shiny flat lesion on the right infe-
rior buttock. At the age of 10 months, this lesion began to
develop intermittent inflammatory cysts with cribriform
scarring, and comedones became apparent. At the time
of enrollment, this lesion extended inferiorly to the post-
ero-medial right thigh and was a 10 cm 3 2 cm plaque
composed of several atrophic cribriform scars and scattered
pink comedones that were surmounted by a thin scale
crust. Inferior to this plaque was a second, similar ap-
pearing one measuring 2 cm 3 1 cm (Figure 1). NC103, a
19-year-old woman, presented with a 1 cm 3 4 cm lesion
on the scalp that appeared at birth and subsequently devel-
oped alopecia, comedones, and rare inflammatory cysts
(Figure 1).
Histopathology of the NC103 lesion revealed follicles
with dilated ostia adjacent to normal follicles. These
abnormal follicles demonstrated acanthosis and papillo-
matosis of the outer root sheath. Furthermore, large cystic
structures filled with keratin were present in the deep
dermis (Figure 1). Examination of tissue from NC101
showed isolated follicles with dilated ostia and acanthosis
and papillomatosis of the outer root sheath. Accumulated
keratin was present without evident hair shafts (Figure 1).an Journal of Human Genetics 98, 1030–1037, May 5, 2016 1031
Sample Position (hg19) Gene
Base
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Protein
 Effect
Reads tissue
ref   nonref
Reads blood
ref   nonref
NC101 chr14:75570544 G>TNEK9 p.Gly572_Glu577del 153  29        91         0 4.3x10-6
NC103 chr14:75587237 T>CNEK9 p.Ile167Thr 226  33              184        0 9.3x10-9
NC102 chr14:75570558 T>CNEK9 p.Ile573Thr  65         12        66         0 4.4x10-4
NC101 chr14:75570561 G>TNEK9 p.Gly572_Glu577del 136  28        82         0 7.0x10-6
coiled-coil
NLS
RCC1 repeats
p.Ile573Thrp.Gly572_Glu577del
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Figure 2. Somatic NEK9 Mutations Cause Nevus Comedonicus
Whole-exome sequencing of DNA isolated from tissue and blood of individuals NC101, NC102, and NC103 was performed (A). Using
MuTect, Perl and Python scripts, we identified tissue-specific SSNVs and indels and ranked them by Fisher’s exact test score. NC101 had
twomutations inNEK9 that were in cis on spanning short reads. These mutations led to a loss of six amino acids in the encoded protein,
p.Gly572_Glu577del, via abolition of the native exon 14 splice donor and utilization of a cryptic splice donor within the coding region
of exon 14 (Figure S3). NC102 had a somatic NEK9 p.Ile573Thr missense variant. NC103 showed a somatic NEK9 p.Ile167Thr missense
variant. No other somaticmutations were found in any of the three individuals with a Fisher’s exact test p value< 13 104, and no non-
reference reads were identified in blood DNA in any individual. Mutations were confirmed with Sanger sequencing (Figure S2). NC101’s
and NC102’s mutations were localized in the RCC1 domain of NEK9, whereas NC103’s mutation was localized in the kinase domain (B).In contrast to the smooth, ordered layer of keratinocytes
seen in the outer root sheath of hair follicles, the acantho-
sis and papillomatosis of cells lining the NC follicle and
cyst regions presented a morphology similar to rete ridges
in interfollicular epidermis. Although lesional tissue was
limited, NC comedonal follicles did not appear to have
associated sebaceous lobules. Interfollicular skin in NC le-
sions was normal on clinical and histologic examination.
These clinical and histologic findings are distinct from
Apert syndrome, Munro acne nevus, and acne inversa.
The characteristic sinus tracts and double comedones of
acne inversa were not observed in any NC lesions. Histo-
logic findings further distinguish Apert syndrome and
Munro acne nevus from NC, given that both demonstrate
a flat, atrophic cyst wall and numerous associated seba-
ceous lobules, in contrast to the papillomatosis and acan-
thosis of the NC follicle and cyst, which also lack sebaceous
lobules.19
We isolated DNA from blood and tissue samples by us-
ing a phenol-chloroform extraction or DNeasy (QIAGEN),
respectively. Using paired samples from each of the three
subjects, we performed whole-exome capture (Roche EZ
exome V3) followed by high-throughput sequencing (Illu-
mina HiSeq 2500), generating average coverage > 903 for
tissue samples and > 853 for blood samples (Table S1).
Sequence was aligned to the human genome reference
(UCSC Genome Browser, hg19) with the Burrows-Wheeler
Aligner (BWA-MEM).20 Reads were then trimmed and PCR
duplicates removed with Picard,21 and resultant BAM files
were calibrated with GATK.21 To identify somatic single-1032 The American Journal of Human Genetics 98, 1030–1037, Maynucleotide variants (SSNVs) present in tissue samples but
absent in the matched blood sample, we employed Mu-
Tect22 and a Fisher’s exact test to compare blood and tissue
read numbers; SSNVs with a p value greater than 1 3 103
were excluded. Remaining SSNVs were annotated with
AnnoVar.23 To exclude common and non-damaging vari-
ants, we further analyzed nonsynonymous exonic and
splice-site SSNVs with a prevalence < 1% in an Exome Ag-
gregation Consortium (ExAC) control dataset (Table S2).
For each of the three paired samples, all of these high-
confidence SSNVs identified were located within a single
gene, NEK9 (MIM: 609798), which encodes a kinase.
These occurred at highly conserved residues, and none
of the mutations were found in >134,000 alleles in
ExAC, Exome Variant Server, and 1000 Genomes con-
trol databases. All were confirmed via Sanger sequencing
(Figure S2). We found no evidence of loss of heterozygosity
or genomic segment amplification or deletion (Figure 2
and Figure S1) in any sample.
To estimate the probability of observing three somatic
mutations clustering within a 3 kb coding region (the
size of NEK9) by chance, we performed a Monte Carlo
simulation, counting the two mutations found in NC101
as a single genetic event. We distributed all three observed
somatic mutations in the three samples across a 31 Mb
coding region and determined the frequency with which
three mutations clustered within a 3 kb segment. In 108
iterations of this simulation, we estimate the probability
of observing a mutation in NEK9 in all three samples to
be approximately 6 3 108.5, 2016
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Figure 3. NEK9 Mutations Cause Increased Phosphorylation of
NEK9
HEK293 cells were transiently transfected with GFP as a negative
control or HA-tagged NEK9 constructs, including those encoding
wild-type (WT) NEK9, p.Gly572_Glu577del NEK9, p.Ile167Thr
NEK9, and p.Ile573Thr NEK9. 24 hr post-transfection with lipo-
fectamine 2000 (Invitrogen), protein lysates were run on SDS-
page gels and transferred to nitrocellulose. Blots were probed
with 1:1,000 anti-HA (ab18181; Abcam), 1:1,000 anti-beta-actin
(A5316; Sigma), 1:10,000 anti-NEK9 (ab138488; Abcam), and
1:250 anti-phospho-NEK9 (ab63553; Abcam). In contrast to
expression of wild-type NEK9, expression of each of the three
mutant constructs led to increased phosphorylation of NEK9
despite equivalent protein expression detected by blotting for
HA, total NEK9, and actin. This experiment was repeated three
times, confirming increased phospho-NEK9 in cells expressing
mutant alleles.This analysis revealed two somatic NEK9 mutations in
cis in individual NC101: c.1731þ1G>T (GenBank: NM_
033116.4), which abolishes a native splice donor, at
the exon 14 and intron 14 junction and c.1715G>T
(p.Gly572Val), which generates a cryptic splice donor
site, within exon 14 (Figure 2). To assess mutation conse-
quence, we cloned a segment containing exons 13 to 15
of wild-type and mutant (c.1715G>T and c.1731þ1G>T)
NEK9 into pcDNA3.1. Resulting constructs were trans-
fected into PLC cells, and we performed RT-PCR 48 hr after
transfection, using RNeasy (QIAGEN) for RNA isolation
and iScript (BD Biosciences) for cDNA generation. PCR
was then used to amplify exons 13 to 15, and products
were Sanger sequenced. This assay demonstrated loss
of 18 nucleotides in the encoded mRNA (p.Gly572_
Glu577del), corresponding to deletion of amino acids
572577 (Figure S3). All six of these amino acids are highly
conserved, demonstrating conservation in 100%, 93%,
84%, 100%, 99%, and 89% of 100 vertebrates, respectively
(Figure S4).
Individual NC102 had a single somatic missense muta-
tion (c.1718T>C [p.Ile573Thr]) in exon 14 of NEK9,
affecting one of the amino acids that we found deleted in
NC101. The isoleucine in this position is conserved in
93% of vertebrates, and no species demonstrates a threo-
nine at this position. The affected amino acids in NC101
and NC102 fall within the regulator of chromosome
condensation-like (RCC1) domain of NEK9 (Figure 2).
Previous reports have shown that deletion of the NEK9
RCC1 domain causes increased kinase activity via auto-The Americphosphorylation, suggesting that the observed mutations
might abrogate RCC1-mediated suppression of NEK9 ki-
nase activity.24
In individual NC103, we found a somatic mutation
(c.500T>C [p.Ile167Thr]) in exon 4 of NEK9, which occurs
in the kinase domain of the protein (Figure 2). This isoleu-
cine residue is 100% conserved in vertebrates (Figure S4).
There is in vitro evidence that the NEK9 kinase and
RCC1 domains bind to each other,24 potentially linking
the NC101 and NC102 mutations within the RCC1
domain to the kinase-domain mutation in NC103.
NEK9 is a serine/threonine kinase that functions as an
important regulator of cell-cycle and checkpoint control
and is a member of a larger family of NEK proteins
that share moderate conservation.24 Phosphorylation by
PLK1 and CDK1 at Ser29, Thr333, Ser750, and Ser869
are required steps for activation of NEK9 and precede
phosphorylation at Thr210, which can also occur auto-
catalytically or via PLK1 action.25 Thr210 lies within the
activation loop of NEK9, and phosphorylation at this resi-
due is required for kinase activity.25
The finding of somatic NEK9 mutations within affected
tissue of three NC-affected subjects is consistent with
either a gain-of-function or a dominant-negative mecha-
nism. To study the effect of these mutations, we obtained
the NEK9 cDNA (Harvard Plasmid) and introduced the
observed mutations via QuikChange Site-Directed Muta-
genesis (Agilent). An HA tag was introduced at the N termi-
nus via PCR, and tagged wild-type and mutant constructs
were transfected into pCAGGS via Gibson assembly (New
England Biolabs). We transiently transfected resulting
cDNAs of wild-type NEK9 and mutants into HEK293 cells
and assayed levels of Thr210-phosphorylated NEK9 by
western blotting. We found that, relative to wild-type, all
three NC mutations significantly increased NEK9 Thr210
phosphorylation (Figure 3). Given prior observations
that Thr210 phosphorylation is necessary for NEK9 kinase
activity, and that NEK9 auto-phosphorylation increases
kinase activity,25 our data support the hypothesis that
NC mutations are gain of function.
Given the presence of independent somatic mutations in
affected tissue of three subjects with NC, including one
lesion with comedones replacing hair follicles on the scalp
(Figure 1), we sought to investigate localization of NEK9 in
hair-bearing skin.Withinnormal skin, immunolocalization
studies showed NEK9 localized to the epidermis and hair
follicles. In both interfollicular epidermis and in affected
dilated follicles of NC tissue, we found no change in subcel-
lular localization in comparison tonormal tissue (Figure S5).
To further explore the consequences of NEK9mutation, we
performed immunolocalization studies employing hair
follicle andepidermal differentiationmarkers inNC lesional
tissue and a normal control after antigen retrieval (incuba-
tion in 10 mM sodium citrate, 0.05% Tween 20 [pH 6.0] at
100C for 20min).We found abnormal localization ofmul-
tiple markers of hair follicle and epidermal differentiation
(Figure 4). Expansion of keratin 15 (K15) immunostainingan Journal of Human Genetics 98, 1030–1037, May 5, 2016 1033
Figure 4. NEK9 Mutation Impairs Follic-
ular Differentiation
In NC103 lesional tissue, follicular differ-
entiation was analyzed by immunofluores-
cence staining. Keratin 5 staining in all
images marks the outer root sheath of the
hair follicle. To characterize the stem cell
pool in NC, staining for keratin 15 (K15)
was performed. K15 localizes to the basal
layer of keratinocytes within the bulge in
normal hair follicles (A), but in NC was
found to strongly localize to the basal layer
throughout the follicle (B) and cyst (C). In
normal tissue, keratin 6, AE15 and AE13
mark follicular differentiation in the com-
panion layer, inner root sheath, and cuticle
and cortex, respectively (D, G, and J). In
NC, these were absent in the upper follic-
ular regions (E, H, and K), as well as within
cysts (F, I, and L), suggesting a shift in
follicular fate to an IFE-like fate within
NC tissue. To further assess differentiation
of follicular cells, keratin 10 (K10) staining
was examined. K10, a marker of suprabasal
IFE, which is absent in sub-bulge regions of
normal follicles (M), was found within
the upper follicular and sub-bulge region
of NC (N) and within the cysts of NC tissue
(O), in both cases maintaining suprabasal
localization. The dermal-epidermal junc-
tion is labeled with a dashed white line in
each panel. Control tissue was obtained
from discarded tips from surgical excision.
Scale bar represents 20 mm in (A)–(C) and
(M)–(O) and 50 mm in (D)–(L).(sc-47697, dilution 1:200; Santa Cruz), a marker of the hair
follicle bulge, which is thought to be the location of the
hair follicle stem cell pool,26 was found in NC follicles ex-
tendingfromtheexpectedbulgesite todermalcysts (Figure4
and Figure S6). Noting this result, we further assessed local-
ization of hair follicle differentiation markers, including
keratin 6 (K6) (prb-169P, 1:200 dilution; Covance), AE15
(ab58755, 1:100 dilution; Abcam) and AE13 (ab16113,
1:100 dilution; Abcam), which define the companion layer,1034 The American Journal of Human Genetics 98, 1030–1037, May 5, 2016inner root sheath, and the cuticle and
cortex, respectively. K6 was absent
within the region of the NC follicular
area and cyst (Figure 4). AE13 and
AE15 were both absent throughout
NC follicles and cysts (Figure 4).
Finding an absence of hair follicle
differentiation markers in NC, we
assessed localization of keratin 10
(K10) (sc-53252, 1:200 dilution; Santa
Cruz), a marker of interfollicular
epidermal differentiation, which is ab-
sent in normal hair follicles. Notably,
K10 was ectopically localized supra-
basally throughout NC follicles and
cysts (Figure 4 and Figure S6). Ki67
(ab15889, 1:300 dilution; Abcam) im-munolocalization was performed to assess proliferation,
and NC and wild-type skin showed a similar fraction of
Ki67-positive basal nuclei, suggesting that comedones are
not the direct result of hyperproliferation within follicles
or cysts (Figure S7). Presence of the interfollicular epidermis
(IFE) marker K10, expansion of the population of cells with
K15 immunostaining, and absence of hair-specific markers
inNCfollicles demonstrates defectivedifferentiationwithin
the NC follicular unit.
Although NEK9 is found in follicle, cyst, and IFE cells,
and we have observed via laser capture that somatic muta-
tion is present in both sites (Figure S2), there is no apparent
clinical or histologic phenotype in the IFE. Differentiation
was assessed via immunolocalization of K10 and filaggrin
in the IFE of NC lesional tissue. The localization and
immunofluorescence intensity of both markers was iden-
tical in normal tissue and in NC IFE (Figure S8).
Mutations in NEK9 paralogs can cause severe pheno-
types. Loss-of-function mutations in NEK1 cause short-
rib polydactyly syndrome (MIM: 263520),27 and recessive
mutations inNEK8 have been implicated inmultiple organ
dysplasia (MIM: 615415).28 Neither NEK1 nor NEK8 have
been shown to interact with NEK9 directly.
NEK6, NEK7, and NEK9 are necessary for proper
assembly of the mitotic spindle via interaction with
EG5, allowing transition from interphase to mitosis.29
NEK2 separately acts in disassembly of the intercentroso-
mal linker.30 Activated NEK9 phosphorylates NEK6 and
NEK7,24,25,31,32 which act on Eg5 to enable chromosome
separation and mitotic spindle formation. NEK9 also func-
tions in replication stress response, activating CHK1,33 and
it has been shown to be critical to proliferation in p53-defi-
cient cancer cells, though there is no evidence that NEK9
interacts with p53 directly.34 Notably, NEK9 has been
found to be weakly expressed in normal lung parenchyma,
but strongly expressed in lung carcinomas of multiple
types, regardless of p53 mutation status, suggesting that
it might be important in neoplasia.34
Recent reports have shown that recessive germline NEK9
mutations cause skeletal disease without cutaneous pheno-
types. Homozygous nonsense mutations in NEK9,
c.1489C>T (p.Arg497*), were found in fetuses with a lethal
skeletal dysplasia in two Irish Traveller families.35 In addi-
tion, a single affected individual has also been described
with a homozygous NEK9 mutation, demonstrating joint
contracture and Legg-Calve´-Perthes (MIM: 150600) dis-
ease.36 Notably, NC syndrome features skeletal abnormal-
ities, including scoliosis, syndactyly or absence of fingers,
and supranumerary digits, suggesting that somatic NEK9
mutation in bone progenitors could account for these
findings.37
Overexpression or knockout of NEK9 and its effectors
leads to severe cellular dysfunction. NEK9 silencing via
RNAi in cell culture prevents effective mitosis, leading
to weak or malformed mitotic spindles.25 Further, over-
expression of NEK9 in cells is toxic, with the majority of
transiently transfected cells unable to successfully prog-
ress through a mitotic cycle.24 Similarly severe findings
are found with lesions in downstream effectors of
NEK9 signaling. Mice with deletion of NEK7 have early
mortality due to failure in cytokinesis, and embryonic
fibroblasts from NEK7-null animals were found to
be polyploid with abnormal cilia morphology.38 Mice
overexpressing Eg5 demonstrate increased propensity for
tumors and genomic instability with poor chromosome
segregation.39The AmericDespite a known role in spindle formation and chromo-
some separation and in checkpoint regulation, our results
further suggest that NEK9 might have additional function
in the epidermis. In NC lesional tissue, the ectopic strong
basal layer localization of K15 in comedonal follicles and
cysts and simultaneous suprabasal localization of K10 sug-
gests a switch in fate of progenitors from hair follicle to an
IFE-like lineage. This switch might account for differentia-
tion defects in NC, which bear some similarities to those
seen in mouse models featuring cystic hair follicles and
IFE-specific localization of differentiation markers in follic-
ular keratinocytes.40–42
Mice with decreased LEF1 signaling due to deletion of
the beta-catenin binding domain of LEF1 develop dermal
cysts that resemble those found in NC on histopathologic
examination. As in NC, these cysts demonstrate suprabasal
K10, but immunolocalization of keratin 6 (K6) is present in
cysts and hair follicles, a finding not seen in NC cysts or
follicles.42 Similarly, defects in Notch signaling due to
loss of mesenchymal RBP-Jk can lead to K10-positive cyst
formation. These lose AE13 and AE15 as seen in NC but
retain K6.40 Finally, K15 conditional SOX9 knockout
mice also develop K10-positive cysts in hair follicles,
though these show normal K6, AE13, and AE15 immuno-
localization, unlike NC.41
These mousemodels demonstrate that several pathways,
involving both epidermal and mesenchymal inputs, can
alter hair follicle progenitor fate. In NC, the loss of normal
follicular differentiation markers, expansion of strongly
K15-positive basal cells, and suprabasal localization of
K10 throughout the follicle and cyst suggests that NC dem-
onstrates a similar type of fate switching. This ‘‘fate switch’’
paradigm might partly help explain why NC has no
evident IFE pathology; if NEK9 mutation drives cells to-
ward an IFE fate, one might expect that cells intended for
such a fate would be less affected or unaffected.
The discovery of somatic NEK9 mutations at highly
conserved sites in three unrelated NC cases, with no evi-
dence for additional somatic mutations within the lesions,
demonstrates that somatic NEK9 mutation causes NC.
NEK9mutations in NC resulted in increased Thr210 phos-
phorylation, suggesting gain of function, and affected tis-
sue showed loss of markers of follicular differentiation
with concurrent gain of an IFE marker. Although NEK9 lo-
calizes to cells within the IFE and hair follicle (Figure S5), is
highly conserved across species (Figure S4), and is known
to act in pathways regulating cell-cycle and checkpoint
control,29 our results suggest that NEK9 might also co-
regulate pathways relevant to follicular cell fate. Given
the aforementioned mouse models featuring phenotypes
similar to NC, it is plausible that NEK9 might function in
theWnt, Notch, or Sox9 signaling pathways. Future exper-
iments addressing these possibilities could reveal a role for
NEK9 in hair follicle fate decisions.
Given that comedone formation is critical step in acne
pathogenesis and that NEK9 mutations in NC appear to
have a follicle-specific effect, it is intriguing to consideran Journal of Human Genetics 98, 1030–1037, May 5, 2016 1035
whether NEK9 and its effectors might contribute to acne
vulgaris pathobiology.Accession Numbers
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